Todd W. Trask
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Todd W. Trask has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
A. Chiocca
1 shared publicationA. R. Chaudhury
1 shared publication- Augusto Rojas-Martinez
Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico
1 shared publication D. Baskin
1 shared publicationE. Aguilar-Cordova
1 shared publicationEstuardo Aguilar-Cordova
1 shared publication
Latest Publications
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 2039
Radiographic and immunologic responses to adjuvant immunotherapy for malignant gliomas
2039 Background: The invasive nature of malignant gliomas leads to a high rate of recurrence. Recruitment of the immune system to eradicate residual tumor may provide a significant outcome improvement. AdV-tk, an adenoviral vector containing the Herpes virus thymidine-kinase gene (GliAtak, Advantagene) plus prodrug has shown promise as an immuno-stimulatory adjuvant to standard therapies. The mechanisms involve tumor cytotoxicity combined with local elicitation of danger signals, recruitment and activation of antigen presenting cells and stimulation of systemic antitumor T- cell immunity. Methods: Patients with newly diagnosed malignant glioma received one of three dose levels of AdV-tk (3×1010, 1×1011 and 3×1011 vector particles) delivered to tumor cells via tumor bed injection followed by valacyclovir 2gm TID×14d. Radiation began within 7 days and temozolomide was allowed after prodrug completion. Results: The study enrolled 3 patients in each of the first two dose levels and 6 in the third. Tumors were classified as WHO grade IV (GBM) in 10 patients and anaplastic astrocytoma in two. Possibly related toxicity included transient elevation of liver transaminase, creatinine and fever. There were no significant related delays or interruptions in radiation or temozolomide. Five patients are alive 12–21 months after treatment. Significant intratumoral T-cell and macrophage infiltrate was seen in two patients who underwent re-resection at 30 and 36 weeks, suggesting a treatment induced antitumor response. One GBM patient, with persistent enhancement and FLAIR signal resolving slowly over 9 months is progression-free >20 months after treatment. Three patients have persistent enhancement and FLAIR signals but no progression for >12 months. Radiation and immune effects may confound interpretation of conventional imaging. Perfusion MRI was used in two of these three patients in an attempt to differentiate tumor progression from treatment effects. Conclusions: AdV-tk can be safely combined with surgery and radio-chemotherapy in patients with newly diagnosed malignant gliomas. Novel imaging techniques may help differentiate tumor progression from inflammation after radio-immunotherapy.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 2039
Radiographic and immunologic responses to adjuvant immunotherapy for malignant gliomas
2039 Background: The invasive nature of malignant gliomas leads to a high rate of recurrence. Recruitment of the immune system to eradicate residual tumor may provide a significant outcome improvement. AdV-tk, an adenoviral vector containing the Herpes virus thymidine-kinase gene (GliAtak, Advantagene) plus prodrug has shown promise as an immuno-stimulatory adjuvant to standard therapies. The mechanisms involve tumor cytotoxicity combined with local elicitation of danger signals, recruitment and activation of antigen presenting cells and stimulation of systemic antitumor T- cell immunity. Methods: Patients with newly diagnosed malignant glioma received one of three dose levels of AdV-tk (3×1010, 1×1011 and 3×1011 vector particles) delivered to tumor cells via tumor bed injection followed by valacyclovir 2gm TID×14d. Radiation began within 7 days and temozolomide was allowed after prodrug completion. Results: The study enrolled 3 patients in each of the first two dose levels and 6 in the third. Tumors were classified as WHO grade IV (GBM) in 10 patients and anaplastic astrocytoma in two. Possibly related toxicity included transient elevation of liver transaminase, creatinine and fever. There were no significant related delays or interruptions in radiation or temozolomide. Five patients are alive 12–21 months after treatment. Significant intratumoral T-cell and macrophage infiltrate was seen in two patients who underwent re-resection at 30 and 36 weeks, suggesting a treatment induced antitumor response. One GBM patient, with persistent enhancement and FLAIR signal resolving slowly over 9 months is progression-free >20 months after treatment. Three patients have persistent enhancement and FLAIR signals but no progression for >12 months. Radiation and immune effects may confound interpretation of conventional imaging. Perfusion MRI was used in two of these three patients in an attempt to differentiate tumor progression from treatment effects. Conclusions: AdV-tk can be safely combined with surgery and radio-chemotherapy in patients with newly diagnosed malignant gliomas. Novel imaging techniques may help differentiate tumor progression from inflammation after radio-immunotherapy.
- Open Access
- 1 February 2000
- Published by Elsevier in Molecular Therapy
- Vol. 1 (2) , 195-203
Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors
- 1 February 2000
- Published by Elsevier in Molecular Therapy
- Vol. 1 (2) , 195-203
Open AccessPhase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors